Although some preliminary studies have revealed the promising potential of Tip60 as a therapeutic target in androgen-dependent prostate cancer, further studies are warranted to explore the effects of Tip60 inhibition on metabolic pathways that are mediated by Tip60 and the AR in different stages of prostate cancer. The gene discussed is KAT5; the disease is prostate cancer.